HomeCompareSWI vs MRK

SWI vs MRK: Dividend Comparison 2026

SWI yields 10.82% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $15.9K in total portfolio value· pulled ahead in Year 8
10 years
SWI
SWI
● Live price
10.82%
Share price
$18.49
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.9K
Annual income
$2,130.34
Full SWI calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — SWI vs MRK

📍 MRK pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSWIMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SWI + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SWI pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SWI
Annual income on $10K today (after 15% tax)
$919.42/yr
After 10yr DRIP, annual income (after tax)
$1,810.79/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $6,517.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SWI + MRK for your $10,000?

SWI: 50%MRK: 50%
100% MRK50/50100% SWI
Portfolio after 10yr
$48.8K
Annual income
$5,964.24/yr
Blended yield
12.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SWI
Analyst Ratings
7
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$13.30
-28.1% upside vs current
Range: $12.50 — $15.00
Altman Z
1.0
Piotroski
7/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SWI buys
0
MRK buys
0
No recent congressional trades found for SWI or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSWIMRK
Forward yield10.82%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$40.9K$56.8K
Annual income after 10y$2,130.34$9,798.13
Total dividends collected$16.0K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$13.30$128.54

Year-by-year: SWI vs MRK ($10,000, DRIP)

YearSWI PortfolioSWI Income/yrMRK PortfolioMRK Income/yrGap
1$11,782$1,081.67$11,206$366.19+$576.00SWI
2$13,797$1,191.01$12,650$502.35+$1.1KSWI
3$16,067$1,303.53$14,407$694.19+$1.7KSWI
4$18,610$1,418.63$16,585$967.82+$2.0KSWI
5$21,448$1,535.70$19,342$1,363.89+$2.1KSWI
6$24,604$1,654.13$22,913$1,947.19+$1.7KSWI
7$28,100$1,773.35$27,662$2,823.89+$438.00SWI
8← crossover$31,959$1,892.81$34,159$4,173.35$2.2KMRK
9$36,209$2,011.97$43,337$6,308.80$7.1KMRK
10$40,873$2,130.34$56,776$9,798.13$15.9KMRK

SWI vs MRK: Complete Analysis 2026

SWIStock

SolarWinds Corporation provides information technology (IT) management software products in the United States and internationally. The company offers a portfolio of solutions to technology professionals for monitoring, managing, and optimizing networks, systems, desktops, applications, storage, databases, website infrastructures, and IT service desks. It provides a suite of network management software that offers real-time visibility into network utilization and bandwidth, as well as the ability to detect, diagnose, and resolve network performance problems; and a suite of infrastructure management products, which monitor and analyze the performance of applications and their supporting infrastructure, including websites, servers, physical, virtual and cloud infrastructure, storage, and databases. The company also provides a suite of application performance management software that enable visibility into log data, cloud infrastructure metrics, applications, tracing, and web performance management; and service management software that offers ITIL-compliant service desk solutions for various companies. It markets and sells its products directly to network and systems engineers, database administrators, storage administrators, DevOps, SecOps, and service desk professionals. The company was formerly known as SolarWinds Parent, Inc. and changed its name to SolarWinds Corporation in May 2018. SolarWinds Corporation was founded in 1999 and is headquartered in Austin, Texas.

Full SWI Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SWI vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SWI vs SCHDSWI vs JEPISWI vs OSWI vs KOSWI vs MAINSWI vs JNJSWI vs ABBVSWI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.